AVP BioPharma Consult ApS: Financial statements 2023
CVR: 37770426
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
AVP BioPharma Consult ApS (CVR 37770426) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 1,008,640 and a net result of DKK 106,199 compared with DKK 148,392 the year before. That is a decrease of 10.4% compared with the year before. Equity in the 2023 report amounted to DKK 225,288. The solvency ratio was 58.2%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 1,008,640
- Profit/Loss
- DKK 106,199
- Equity
- DKK 225,288
- Total Assets
- DKK 387,389
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 1M | 106K | 225K | 1 |
| 2022 | - | 1.1M | 148K | 294K | 1 |
| 2021 | - | 1.2M | 261K | 346K | 1 |
| 2020 | - | 1.1M | 190K | 295K | 1 |
| 2019 | - | 1.5M | 320K | 375K | 1 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
AVP BioPharma Consult ApS has published its annual report for 2022. Gross profit came to DKK 1,125,468, and the net result was DKK 148,392.
About AVP BioPharma Consult ApS
AVP BioPharma Consult ApS is a Danish company of the type Anpartsselskab based in Virum, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Anders Vagnø Pedersen. The company is owned by AVP Holdings ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 1,249,151 and a net result of DKK 247,464 compared with DKK 237,789 the year before. Equity in the 2025 report amounted to DKK 320,541.
